Science

The neurotransmitter dopamine underlies the brain’s exquisitely precise regulation of physical movement. The neurotransmitter glutamate accounts for more than 80% of the brain’s activity. Restoring dopamine and glutamate balance is the key to reducing symptoms and improving health and well-being for many people with serious neuropsychiatric conditions.

Tourette Syndrome

Children and adults with Tourette Syndrome experience involuntary repetitive movements and vocalize sounds or words that they cannot control, and often struggle with other serious neuropsychiatric conditions.

Autism Spectrum Disorder

Children and adults with Autism Spectrum Disorder may struggle with social interactions, learning and communicating, become easily overwhelmed, and get stuck in loops of behavior or thinking.

Other indications

EuMentis is evaluating other neuropsychiatric conditions that involve glutamate or dopamine imbalance for low-trapping NMDA antagonists, EM-221, or other novel compounds derived from its platforms.

EM-221, a PDE10A Inhibitor

EM-221 precisely modulates dopaminergic brain circuits that are believed to cause the unwanted movements and vocalizations in children and adults with Tourette Syndrome. Because its mechanism of action is highly specific to the brain’s movement centers, it is expected to be much safer than antipsychotics, which are approved and effective but have serious and sometimes long-term side effects.

See how EM-221 works for Tourette Syndrome

GPe = globus pallidus externus
STN == subthalamic nucleus
GPi = globus pallidus internus
SNc = substantia nigra pars compacta

GPe = globus pallidus externus
STN == subthalamic nucleus
GPi = globus pallidus internus
SNc = substantia nigra pars compacta

Brain Circuits

Tourette syndrome is believed to be caused by overactive neuronal pathways that generate tics in the parts of the brain that regulate and coordinate motor movement and speech, including the basal ganglia and its connecting circuits.

In the Striatum

Inside the neuron, the PDE10A enzyme normally breaks down cAMP, reducing their levels inside the cell. EM-221 inhibits this enzyme, increasing levels of cAMP inside the cell. The overall effect is to inhibit neuronal signaling in the dopamine indirect pathways, restoring normal balance in the regulation of movement.

Noncompetitive low-trapping NMDA antagonist

EuMentis is developing a noncompetitive, low-trapping glutamate antagonist designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients who are most likely to benefit.

Autism Spectrum Disorder

So far, there are no approved medications for this condition, although an imbalance in regulation of brain glutamate may underly ASD. A low-trapping NMDA antagonist can restore glutamate equilibrium without causing new and serious side effects.

See how an NMDA antagonist can work for Autism Spectrum Disorder

EuMentis Product Pipeline

Product
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Pivotal Study

EM-221

Tourette Syndrome

EM-221

Tourette Syndrome

Discovery
Preclinical
Phase 1
Phase 2
Phase 2

NMDA antagonist

for Autism Spectrum disorder

NMDA antagonist

for Autism Spectrum disorder

Discovery
Preclinical
Phase 1
Phase 2
Phase 2